LovegroveFESauderMBMuftiA, et al. Navigating bullous pemphigoid: consensus recommendations for diagnosis and management—a Canadian perspective. J Cutan Med Surg. 2025;2025:12034754251351854. doi:10.1177/12034754251351854
2.
KhattabSWanGXuS, et al. Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events. J Immunother Cancer. 2025;13(5):e010638. doi:10.1136/jitc-2024-010638
3.
FournierCHirschISpreaficoAButlerMODhaniNSauderMB.Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: a case series and review of the literature. SAGE Open Med Case Rep. 2023;11:2050313X231195462. doi:10.1177/2050313X231195462
4.
CaoPXuWZhangL.Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022;13:928621. doi:10.3389/fimmu.2022.928621
5.
ChenJXuDHeZ, et al. Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: a case report and review of the literature. Clin Cosmet Investig Dermatol. 2024;17:2865-2874. doi:10.2147/CCID.S487711
